Companies: 10,795·Total market cap: $144.5T
Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd.

DRTSNASDAQHealthcare● Active
$9.28
$-0.07(-0.75%)
Market Cap$838224129
P/E Ratio
52W High$11.62
52W Low$2.81

Alpha Tau Medical Ltd. (DRTS) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

drts · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Alpha Tau Medical Ltd. (DRTS) measures how much investors pay for each dollar of the company's trailing earnings. DRTS's current PE ratio of N/A is calculated by dividing its stock price of $9.28 by its TTM earnings per share of -$0.63.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.51
Based on 4 analysts
EPS (TTM)
-$0.63
TTM · diluted EPS
PEG Ratio
0.41
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Alpha Tau Medical Ltd. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd.You
DRTS
$838MN/A-$0.63
AC Immune S.A.
AC Immune S.A.
ACIU
$223MN/A-$0.70
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc.
ALDX
$105MN/A-$0.56
Amarin Corporation plc
Amarin Corporation plc
AMRN
$294MN/A-$1.87
Alto Neuroscience, Inc.
Alto Neuroscience, Inc.
ANRO
$640MN/A-$2.19
Candel Therapeutics, Inc.
Candel Therapeutics, Inc.
CADL
$467MN/A-$0.72
Cellectis S.A.
Cellectis S.A.
CLLS
$294MN/A-$0.67

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.53
2024-12-31
FY2024
$-0.45
2023-12-31
FY2023
$-0.42
2022-12-31
FY2022
$-0.53
2021-12-31
FY2021
$-0.67
2020-12-31
FY2020
$-0.22
2019-12-31
FY2019
$-0.13

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Alpha Tau Medical Ltd. (DRTS) measures how much investors pay for each dollar of the company's trailing earnings. DRTS's current PE ratio of N/A is calculated by dividing its stock price of $9.28 by its TTM earnings per share of -$0.63.

PE Ratio = Stock Price ÷ EPS (TTM)
= $9.28 ÷ -$0.63 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

DRTS pe ratio · 6 questions

DRTS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $9.28 and TTM EPS of -$0.63. Data sourced from Financial Modeling Prep via DRTS's SEC 10-K and 10-Q filings.

DRTS PE ratioWhat is DRTS PE ratioCurrent PE ratio of DRTSDRTS PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Alpha Tau Medical Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08